These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8033141)

  • 21. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
    Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
    Wadler S; Haynes H; Rozenblit A; Hu X; Kaleya R; Wiernik PH
    Cancer J Sci Am; 1998; 4(5):331-7. PubMed ID: 9815298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
    Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK
    J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
    Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
    J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
    Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
    Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
    Kurzrock R; Quesada JR; Rosenblum MG; Sherwin SA; Gutterman JU
    Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.
    Logan TF; Gooding W; Kirkwood JM; Shadduck RK
    Exp Hematol; 1996 Jan; 24(1):49-53. PubMed ID: 8536792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma.
    Hübel K; Dale DC; Liles WC
    J Infect Dis; 2002 May; 185(10):1490-501. PubMed ID: 11992286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
    Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
    Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
    Bock SN; Cameron RB; Kragel P; Mulé JJ; Rosenberg SA
    Cancer Res; 1991 May; 51(10):2649-54. PubMed ID: 2021943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-10 contributes development of macrophage suppressor activities by macrophage colony-stimulating factor, but not by granulocyte-macrophage colony-stimulating factor.
    Mochida-Nishimura K; Akagawa KS; Rich EA
    Cell Immunol; 2001 Nov; 214(1):81-8. PubMed ID: 11902832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.